Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
February 23, 2022
RegMed Investors’ (RMi) closing bell: what happened, blood from the past and on-going sessions drowns sentiment
February 22, 2022
RegMed Investors’ (RMi) closing bell: stuck in the penalty box
February 18, 2022
RegMed Investors’ (RMi) closing bell: what has changed, an escalation of fears
February 17, 2022
RegMed Investors’ (RMi) closing bell: yet another cell and gene therapy sector sell-off
February 16, 2022
RegMed Investors’ (RMi) closing bell: the sectors back to its losing way
February 15, 2022
RegMed Investors’ (RMi) closing bell: a beautiful day in the sector’s neighborhood
February 14, 2022
RegMed Investors’ (RMi) closing bell: interpreting the cell and gene therapy sector’s decline
February 11, 2022
RegMed Investors’ (RMi) closing bell: the week ends with an empty bottle of cell and gene therapy advancements
February 10, 2022
RegMed Investors’ (RMi) closing bell: cell and gene sector gets shot down and crashes in flames
February 9, 2022
RegMed Investors’ (RMi) closing bell: riding the sector merry-go-round
35 companies, 1 interpreter!
Insight, foresight and recommendation
Stemline Therapeutics (STML) -- STML opened on 1/2/18 at $15.65 and closed on 3/31 at $15.85 and March at $16.75 with a high (3/6/18) at 17.20 ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors